Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease.
Aged
Canada
/ epidemiology
Cohort Studies
Dyspnea
/ diagnosis
Female
Humans
Lung Diseases, Interstitial
/ diagnosis
Male
Middle Aged
Prospective Studies
Pulmonary Fibrosis
/ diagnosis
Registries
/ standards
Reproducibility of Results
Surveys and Questionnaires
/ standards
Vital Capacity
/ physiology
Dyspnea
Interstitial lung disease
Minimum clinically important difference
Pulmonary fibrosis
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
08 Jul 2021
08 Jul 2021
Historique:
received:
13
05
2021
accepted:
29
06
2021
entrez:
9
7
2021
pubmed:
10
7
2021
medline:
4
1
2022
Statut:
epublish
Résumé
The University of California, San Diego Shortness of Breath Questionnaire (UCSDSOBQ) is a frequently used domain-specific dyspnea questionnaire; however, there is little information available regarding its use and minimum important difference (MID) in fibrotic interstitial lung disease (ILD). We aimed to describe the key performance characteristics of the UCSDSOBQ in this population. UCSDSOBQ scores and selected anchors were measured in 1933 patients from the prospective multi-center Canadian Registry for Pulmonary Fibrosis. Anchors included the St. George's Respiratory Questionnaire (SGRQ), European Quality of Life 5 Dimensions 5 Levels questionnaire (EQ-5D-5L) and EQ visual analogue scale (EQ-VAS), percent-predicted forced vital capacity (FVC%), diffusing capacity of the lung for carbon monoxide (DLCO%), and 6-min walk distance (6MWD). Concurrent validity, internal consistency, ceiling and floor effects, and responsiveness were assessed, followed by estimation of the MID by anchor-based (linear regression) and distribution-based methods (standard error of measurement). The UCSDSOBQ had a high level of internal consistency (Cronbach's alpha = 0.97), no obvious floor or ceiling effect, strong correlations with SGRQ, EQ-5D-5L, and EQ-VAS (|r| > 0.5), and moderate correlations with FVC%, DLCO%, and 6MWD (0.3 < |r| < 0.5). The MID estimate for UCSDSOBQ was 5 points (1-8) for the anchor-based method, and 4.5 points for the distribution-based method. This study demonstrates the validity of UCSDSOBQ in a large and heterogeneous population of patients with fibrotic ILD, and provides a robust MID estimate of 5-8 points.
Identifiants
pubmed: 34238283
doi: 10.1186/s12931-021-01790-0
pii: 10.1186/s12931-021-01790-0
pmc: PMC8265065
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
202Subventions
Organisme : Boehringer Ingelheim
ID : 20R23666
Organisme : China Scholarship Council
ID : 201906260235
Références
COPD. 2015 Feb;12(1):31-7
pubmed: 24915470
Turk J Emerg Med. 2018 Aug 07;18(3):91-93
pubmed: 30191186
Respir Med. 2010 Sep;104(9):1350-5
pubmed: 20471238
Am J Respir Crit Care Med. 2017 Nov 15;196(10):1249-1254
pubmed: 28414524
Chest. 2018 Nov;154(5):1061-1069
pubmed: 30201408
Respir Med. 2012 Oct;106(10):1447-55
pubmed: 22801586
Respir Res. 2020 Mar 12;21(1):68
pubmed: 32164673
Lancet Respir Med. 2020 Feb;8(2):147-157
pubmed: 31578169
COPD. 2005 Mar;2(1):105-10
pubmed: 17136970
BMC Pulm Med. 2019 Nov 27;19(1):223
pubmed: 31771541
Chest. 2020 Jul;158(1S):S49-S56
pubmed: 32658652
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
J Cardiopulm Rehabil. 2005 Nov-Dec;25(6):370-7
pubmed: 16327533
N Engl J Med. 2019 Oct 31;381(18):1718-1727
pubmed: 31566307
Int J Behav Med. 1995;2(2):118-34
pubmed: 16250781
Chest. 1998 Mar;113(3):619-24
pubmed: 9515834
J Clin Epidemiol. 1999 Sep;52(9):861-73
pubmed: 10529027
Can Respir J. 2016;2016:3562923
pubmed: 27445528
Int J Med Educ. 2011 Jun 27;2:53-55
pubmed: 28029643
N Engl J Med. 2014 May 29;370(22):2083-92
pubmed: 24836312
Thorax. 2021 Jan;76(1):37-43
pubmed: 33023996
Rheumatology (Oxford). 2015 Aug;54(8):1369-79
pubmed: 25667436
Lancet Respir Med. 2020 Jan;8(1):25-33
pubmed: 31575509
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Respir Med. 2010 Feb;104(2):296-304
pubmed: 19815403
Eur Respir J. 2019 Sep 5;54(3):
pubmed: 31221807
Med Care. 2016 Jan;54(1):98-105
pubmed: 26492214
Am J Respir Crit Care Med. 2011 Dec 15;184(12):1382-9
pubmed: 21940789
N Engl J Med. 2020 Sep 3;383(10):958-968
pubmed: 32877584
Am J Respir Crit Care Med. 2011 May 1;183(9):1231-7
pubmed: 21131468
COPD. 2014 Feb;11(1):26-32
pubmed: 23886071